European Commission has approved Gilead's Lenacapavir under the brand name Sunlenca®. It is the first long-acting HIV capsid inhibitor in its class to be approved in the European Union for the treatment of HIV infection in combination with other antiretroviral drugs in people with multidrug-resistant HIV who have undergone intensive treatment. The FDA will review the drug's application for approval on December 27, 2022.